← Leaderboards
Rahmi Oklu
Mayo Clinic Arizona
$9,676,744
Attributed
$16,310,514
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,310,514 · 8
By mechanism
R01$15,739,014 · 6
R21$484,500 · 1
R03$87,000 · 1
Top collaborators
- Ali Khademhosseini19 shared
- Y. Shrike Zhang4 shared
Most similar at Mayo Clinic Arizona
Same institution · by research overlap
- Ali Khademhosseini$21,426,218
Others in their field
Top investigators on “Catheters”
- Daniel F Hanley · Johns Hopkins University$32,311,178
- Henry R Halperin · Johns Hopkins University$27,618,868
- Suresh Vedantham · Washington University$19,226,475
- Garret A Fitzgerald · University Of Pennsylvania$16,354,119
- Guillermo J. Tearney · Massachusetts General Hospital$14,190,544
- Pierre E Dupont · Boston University (Charles River Campus)$13,072,394
Research focus
CathetersIn VivoIn VitroPropertyPerformanceBiocompatible MaterialsFormulationThinnessInjectableMinimally InvasiveTherapeutic EmbolizationImageBiomedical EngineeringHistologyMedicalRattusPreventCoupledBaseEngineeringSafetyMorbidity - Disease RateMortalityBiomaterial Compatibility
Grant awards (29)
Drug eluting injectable biomaterials for next generation chemoembolization$617,904
R01 · FY2025 · CA · contact PI
Biomaterials for embolization and ablation of arterio-venous malformations$608,052
R01 · FY2025 · HL · contact PI
Healing enterocutaneous fistulas using bioengineered biomaterials$511,541
R01 · FY2025 · DK · contact PI
Biomaterials for embolization and ablation of arterio-venous malformations$595,892
R01 · FY2024 · HL · contact PI
Drug eluting injectable biomaterials for next generation chemoembolization$587,009
R01 · FY2024 · CA · contact PI
Healing enterocutaneous fistulas using bioengineered biomaterials$547,832
R01 · FY2024 · DK · contact PI
Biomaterials for embolization and ablation of arterio-venous malformations$682,752
R01 · FY2023 · HL · contact PI
Drug eluting injectable biomaterials for next generation chemoembolization$637,881
R01 · FY2023 · CA · contact PI
Healing enterocutaneous fistulas using bioengineered biomaterials$572,891
R01 · FY2023 · DK · contact PI
Biomaterials for embolization and ablation of arterio-venous malformations$699,252
R01 · FY2022 · HL · contact PI
Drug eluting injectable biomaterials for next generation chemoembolization$650,424
R01 · FY2022 · CA · contact PI
Healing enterocutaneous fistulas using bioengineered biomaterials$591,580
R01 · FY2022 · DK · contact PI
Drug eluting injectable biomaterials for next generation chemoembolization$680,198
R01 · FY2021 · CA · contact PI
Treatment of arterial aneurysms using an injectable biomaterial$607,500
R01 · FY2021 · HL · contact PI
Hemorrhage control in the irreversible anticoagulated patient$576,210
R01 · FY2021 · HL · contact PI
Treatment of arterial aneurysms using an injectable biomaterial$636,694
R01 · FY2020 · HL · contact PI
Hemorrhage control in the irreversible anticoagulated patient$577,027
R01 · FY2020 · HL · contact PI
Targeted chemotherapy delivery and capture$538,425
R01 · FY2020 · EB · contact PI
Treatment of arterial aneurysms using an injectable biomaterial$683,811
R01 · FY2019 · HL · contact PI
Hemorrhage control in the irreversible anticoagulated patient$594,098
R01 · FY2019 · HL · contact PI
Targeted chemotherapy delivery and capture$541,013
R01 · FY2019 · EB · contact PI
Treatment of arterial aneurysms using an injectable biomaterial$701,500
R01 · FY2018 · HL · contact PI
Hemorrhage control in the irreversible anticoagulated patient$594,339
R01 · FY2018 · HL · contact PI
Targeted chemotherapy delivery and capture$538,020
R01 · FY2018 · EB · contact PI
Hemorrhage control in the irreversible anticoagulated patient$614,299
R01 · FY2017 · HL · contact PI
Targeted chemotherapy delivery and capture$552,870
R01 · FY2017 · EB · contact PI
Catheter guided endovascular electric field ablation for thrombosis therapy.$254,750
R21 · FY2017 · EB · contact PI
Catheter guided endovascular electric field ablation for thrombosis therapy.$229,750
R21 · FY2016 · EB · contact PI
Circulating tumor cells in hepatocellular carcinoma$87,000
R03 · FY2013 · CA · contact PI